Mechanism of Action of Opioids and Clinical Effects

Freye, Enno; Levy, Joseph V.

doi:10.1007/978-1-4020-5947-6_2

Cited by 8 publications

(9 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Yeh et al (2008) have confirmed that the analgesic effect of a 1:1 ratio of morphine:nalbuphine is superior to the other ratio groups (1:3 or 3:1) for PCIA after gynecologic operations. Also as 100 µ g of sufentanil is commonly used for PCIA, hence equivalent doses of nalbuphine (100 mg) and sufentanil (100 μ g) were evaluated and compared in our study ( Freye and Levy, 2008 ; Robert et al, 2015 ). The onset and duration of analgesic action of nalbuphine are similar to those of morphine, moreover, nalbuphine has a better safety profile with a lower incidence of adverse reactions like pruritus and respiratory depression) ( Zeng et al, 2015 ).…”

Section: Discussionmentioning

confidence: 99%

Analgesic Effect Comparison Between Nalbuphine and Sufentanil for Patient-Controlled Intravenous Analgesia After Cesarean Section

et al. 2020

View full text Add to dashboard Cite

Background: Efficient maternal pain relief after cesarean delivery remains challenging, but it is important to improve outcomes for the mother and the newborn during the puerperium. We compared the analgesic effect of nalbuphine (a κ receptor agonist/μ receptor antagonistic) with that of sufentanil (a µ-receptor agonist) in patient-controlled intravenous analgesia (PCIA) after cesarean section.Methods: We enrolled 84 patients scheduled for elective cesarean sections with spinal anesthesia and randomized them into either nalbuphine or sufentanil groups (42 patients each). Pain scores, PCIA drug consumptions, degree of satisfaction, and adverse events were recorded as outcome measures.Results: The pain scores at rest and uterine cramping pain scores in the nalbuphine group were lower than those in the sufentanil group at 6, 12, and 24 h after the operation. Also, the pain scores while switching to a seated position were lower in the nalbuphine group than in the sufentanil group at 6 and 12 h after the operation (p < 0.05). We found no significant differences in the PCIA drug consumption between the two groups. The degree of satisfaction in patients in the nalbuphine group was higher than that of patients in the sufentanil group (p = 0.01). Adverse events did not differ in the two groups.Conclusion: PCIA with nalbuphine provides better analgesia and higher patient satisfaction than sufentanil after cesarean section.

show abstract

Section: Discussionmentioning

confidence: 99%

Analgesic Effect Comparison Between Nalbuphine and Sufentanil for Patient-Controlled Intravenous Analgesia After Cesarean Section

et al. 2020

View full text Add to dashboard Cite

show abstract

“…1). This fact could not be explained by different analgesic potencies of remifentanil and fentanyl (6–8,16) or age‐related differences in pharmacokinetics profiles of the children (8). Hence, additional investigations are warranted to clarify this issue.…”

Section: Discussionmentioning

confidence: 99%

Remifentanil Versus Fentanyl for Esophagogastroduodenoscopy in Children

Hirsh¹,

Lerner²,

Shnaider³

et al. 2010

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

show abstract

“…are not readily prescribed in the treatment of OA. Opioid analgesics are agonists of the opioid receptors in the central nervous system (CNS), whose activation leads to CNS depression [ 20 ]. They have a well-known side-effect profile, including constipation, nausea, and vomiting, in addition to their very high addiction potential.…”

Section: Peroral Treatmentmentioning

confidence: 99%

Comprehensive Review of Knee Osteoarthritis Pharmacological Treatment and the Latest Professional Societies’ Guidelines

Primorac

Molnar

Matišić³

et al. 2021

Pharmaceuticals

View full text Add to dashboard Cite

Osteoarthritis is the most common musculoskeletal progressive disease, with the knee as the most commonly affected joint in the human body. While several new medications are still under research, many symptomatic therapy options, such as analgesics (opioid and non-opioid), nonsteroid anti-inflammatory drugs, symptomatic slow-acting drugs in osteoarthritis, and preparations for topical administration, are being used, with a diverse clinical response and inconsistent conclusions across various professional societies guidelines. The concept of pharmacogenomic-guided therapy, which lies on principles of the right medication for the right patient in the right dose at the right time, can significantly increase the patient’s response to symptom relief therapy in knee osteoarthritis. Corticosteroid intra-articular injections and hyaluronic acid injections provoke numerous discussions and disagreements among different guidelines, even though they are currently used in daily clinical practice. Biological options, such as platelet-rich plasma and mesenchymal stem cell injections, have shown good results in the treatment of osteoarthritis symptoms, greatly increasing the patient’s quality of life, especially when combined with other therapeutic options. Non-inclusion of the latter therapies in the guidelines, and their inconsistent stance on numerous therapy options, requires larger and well-designed studies to examine the true effects of these therapies and update the existing guidelines.

show abstract

Mechanism of Action of Opioids and Clinical Effects

Cited by 8 publications

References 132 publications

Analgesic Effect Comparison Between Nalbuphine and Sufentanil for Patient-Controlled Intravenous Analgesia After Cesarean Section

Analgesic Effect Comparison Between Nalbuphine and Sufentanil for Patient-Controlled Intravenous Analgesia After Cesarean Section

Remifentanil Versus Fentanyl for Esophagogastroduodenoscopy in Children

Comprehensive Review of Knee Osteoarthritis Pharmacological Treatment and the Latest Professional Societies’ Guidelines

Contact Info

Product

Resources

About